BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more
BioCryst Pharmaceuticals Inc (BCRX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -2.317x
Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) has a cash flow conversion efficiency ratio of -2.317x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($276.04 Million) by net assets ($-119.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioCryst Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioCryst Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioCryst Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Select Medical Holdings
NYSE:SEM
|
0.086x |
|
Guangdong Advertising Co Ltd
SHE:002400
|
0.025x |
|
Boxer Retail Ltd
JSE:BOX
|
0.878x |
|
Innospec Inc
NASDAQ:IOSP
|
0.030x |
|
JAPAN AIRPORT TER.
F:0JA
|
N/A |
|
Tecan Group AG
SW:TECN
|
0.048x |
|
GalaxyCore Inc
SHG:688728
|
0.020x |
|
CHUGOKU EL. PWR
F:59K
|
N/A |
Annual Cash Flow Conversion Efficiency for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of BioCryst Pharmaceuticals Inc from 1994 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-119.15 Million | $329.88 Million | -2.769x | -2632.95% |
| 2024-12-31 | $-475.93 Million | $-52.02 Million | 0.109x | -47.67% |
| 2023-12-31 | $-455.53 Million | $-95.14 Million | 0.209x | -61.98% |
| 2022-12-31 | $-294.60 Million | $-161.85 Million | 0.549x | -58.65% |
| 2021-12-31 | $-106.99 Million | $-142.16 Million | 1.329x | -81.35% |
| 2020-12-31 | $-19.26 Million | $-137.22 Million | 7.124x | +404.18% |
| 2019-12-31 | $38.25 Million | $-89.58 Million | -2.342x | -24.57% |
| 2018-12-31 | $49.23 Million | $-92.56 Million | -1.880x | -282.78% |
| 2017-12-31 | $83.77 Million | $-41.14 Million | -0.491x | +98.55% |
| 2016-12-31 | $1.58 Million | $-53.44 Million | -33.864x | -12221.93% |
| 2015-12-31 | $47.72 Million | $-13.12 Million | -0.275x | +46.08% |
| 2014-12-31 | $75.64 Million | $-38.55 Million | -0.510x | -102.16% |
| 2013-12-31 | $-1.13 Million | $-26.53 Million | 23.561x | -71.40% |
| 2012-12-31 | $-454.00K | $-37.40 Million | 82.372x | +3881.60% |
| 2011-12-31 | $14.81 Million | $-32.25 Million | -2.178x | -408.23% |
| 2010-12-31 | $66.62 Million | $-28.55 Million | -0.429x | -127.97% |
| 2009-12-31 | $86.27 Million | $-16.22 Million | -0.188x | +58.19% |
| 2008-12-31 | $46.43 Million | $-20.87 Million | -0.450x | -16.74% |
| 2007-12-31 | $64.91 Million | $-25.00 Million | -0.385x | +46.44% |
| 2006-12-31 | $21.16 Million | $-15.21 Million | -0.719x | -79.99% |
| 2005-12-31 | $58.44 Million | $-23.35 Million | -0.399x | +35.44% |
| 2004-12-31 | $29.33 Million | $-18.15 Million | -0.619x | -57.22% |
| 2003-12-31 | $28.45 Million | $-11.20 Million | -0.394x | +3.49% |
| 2002-12-31 | $40.13 Million | $-16.36 Million | -0.408x | -128.07% |
| 2001-12-31 | $56.81 Million | $-10.16 Million | -0.179x | -245.95% |
| 2000-12-31 | $61.48 Million | $-3.18 Million | -0.052x | +24.69% |
| 1999-12-31 | $71.40 Million | $-4.90 Million | -0.069x | +54.74% |
| 1998-12-31 | $27.70 Million | $-4.20 Million | -0.152x | +62.76% |
| 1997-12-31 | $25.30 Million | $-10.30 Million | -0.407x | -111.94% |
| 1996-12-31 | $35.40 Million | $-6.80 Million | -0.192x | +71.81% |
| 1995-12-31 | $11.30 Million | $-7.70 Million | -0.681x | -17.41% |
| 1994-12-31 | $11.20 Million | $-6.50 Million | -0.580x | -- |